MC Ozelo¹, J. Mahlangu², KJ. Pasi³, A. Giermasz⁴, AD Leavitt⁵, M. Laffan⁶, E. Symington⁷, DV Quon⁸, J.-D. Wang⁹, K. Peerlinck¹¹, S. Pipe¹¹, B. Madan¹², NS -nøgle¹³, GF Pierce¹⁴, B. O'Mahony^15,16, R. Kaczmarek^17,18, A. Lawal¹⁹, M. Huang¹⁹, WY Wong¹⁹, B. Kim¹⁹, GENEr8-1 prøvegruppe

¹Hemocentro UNICAMP, Institut for Intern Medicin, Institut for Medicinsk Videnskab, University of Campinas, Campinas, Brasilien

²Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand og NHLS, Johannesburg, Sydafrika

³Barts og London School of Medicine and Dentistry, London, Storbritannien

⁴Hemophilia Treatment Center, University of California Davis, Sacramento, USA

⁵University of California, San Francisco, USA

⁶Center for Hematology, Imperial College London, London, Storbritannien

⁷Cambridge University Hospitals NHS Foundation Trust, Cambridge, Storbritannien

⁸Orthopedic Hemophilia Treatment Center, Los Angeles, USA

⁹Center for sjælden sygdom og hæmofili, Taichung Veterans General Hospital, Taichung, Taiwan, Kina

¹⁰Institut for Vaskulær Medicin og Hæmostase og Hæmofili Center, Universitetshospitaler Leuven, Leuven, Belgien

¹¹Department of Pediatrics and Pathology, University of Michigan, Ann Arbor, USA

¹²Guy's & St. Thomas 'NHS Foundation Trust, London, Storbritannien

¹³UNC Blood Research Center, University of North Carolina, Chapel Hill, USA

¹⁴Uafhængig konsulent, La Jolla, USA

¹⁵Irish Haemophilia Society, Dublin, Irland

¹⁶Trinity College, Dublin, Irland

¹⁷Department of Pediatrics, Indiana University School of Medicine, IUPUI-Wells Center for Pediatric Research, Indianapolis, USA

¹⁸Laboratorium for glykobiologi, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Polen

¹⁹BioMarin Pharmaceutical Inc., Novato, USA